Lynk Pharmaceuticals Co. Ltd., a China-based clinical stage company, announced on Wednesday that it dosed the first patient with LNK01001 in its Phase II clinical trial aimed at ankylosing spondylitis, a chronic inflammatory disorder of unknown origin that primarily affects the spine, sternum, and large joints in the body.
LNK01001 is a JAK1 selective inhibitor intended to treat autoimmune diseases.
This study is a randomised, double-blind, placebo-controlled Phase II study assessing the safety and efficiency of LNK01001 capsules in patients with active ankylosing spondylitis. LNK01001 completed phase one clinical studies in healthy subjects in China and in Australia in the summer of 2021, sponsored by Lynk Pharmaceuticals and its US partner, respectively, and Phase II clinical studies for rheumatoid arthritis are presently underway.
Charles River Laboratories launches AMAP to reduce animal testing reliance
PureTech completes enrollment in Phase 2b ELEVATE IPF trial for LYT-100
Cybin secures additional US patent for CYB003 breakthrough therapy programme
GSK's meningitis vaccine candidate accepted for FDA review
Innovent Biologics names new Oncology CMO
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Biophytis reinforces obesity IP with new patent application
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Fusion Antibodies plc secures contract for OptiPhage library development
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
AbbVie announces interim evaluation of Atogepant Phase three, open-label 156-week extension study